Methyl dihydrojasmonate (MDJ) was evaluated for developmental toxicity in presumed pregnant Sprague-Dawley rats at oral dosages of 0,40, 80 or 120 mg/kg/day in corn oil administered on gestational days 7 to 20. MDJ-related maternal clinical signs included an increased incidence of sparse hair coat and ungroomed appearance at 120 mg/kg/day. Two dams in this group also had tan areas in the liver and a pale spleen. The 120 mg/kg/day dosage also caused reduced mean maternal body weight gains and body weights during the dosage period and reduced absolute and relative maternal feed consumption for the entire dosage period. It was concluded that MDJ is not a developmental toxicant in rats under the conditions of this study.

Human MCF-7 breast cancer cells were incubated for 24 hours to allow cell adhesion before exposure to methyl dihydrojasmonate to concentrations of 0, 5, 12.5, 25, and 50 microL/mL (delivered in its pure form as an oily liquid). and 0, 25, 50, 75, 100 microL/mL (delivered as a microemulsion formula including 39% Oleic acid: MDHJ, 1% water and 60% Labrasol: Transcutol P). Monolayer cells were incubated with methyl dihydrojasmonates for 48 hours at 37 deg-C and in an atmosphere of 5% CO2. After 48 hours cells were fixed, washed, and stained with Sulfo-Rhodamine-B (SRB). The survival curve was determined from the surviving fraction and the drug concentration. The formulated methyl dihydrojasmonate demonstrated an IC50 of 42.2 micro-L/mL compared to 3.85 micro-L/mL for the pure compound.